Amifampridine Gets Go-Ahead as LEMS Treatment in Pediatric Patients
May 13th 2019The amifampridine tablets are the first approved therapy specifically indicated for the treatment of pediatric patients with LEMS, a rare autoimmune disorder with neuromuscular symptoms caused by affected nerve connections and muscle weakness.
Valbenazine Data Delivers Vital View of the Impact of Tardive Dyskinesia on Patients
May 10th 2019The chief medical officer of Neurocrine Biosciences spoke about how long-term data on valbenazine (Ingrezza) has helped shape the understanding of the effect tardive dyskinesia can have on patients, and how it can inform better utilization of the medication.
Huma Sheikh, MD: Complementary Approaches for Multimodal Migraine Treatment
May 10th 2019The assistant professor of neurology at Mount Sinai Health System spoke about the recent trend toward approaching migraine in a more holistic fashion, and the incorporation of nonpharmacologic options for patients with the chronic headache condition.
Ozanimod Reduces Grey Matter Loss in Relapsing Multiple Sclerosis
May 9th 2019Compared to interferon beta-1a, the reduction of grey matter volume loss was greater in those treated with both doses of the oral S1P receptor modulator across all age groups, including the youngest patients at the highest risk for brain volume loss.
Jessica Robinson-Papp, MD: Medical Marijuana for Neurologic Conditions
May 8th 2019The professor of neurology at the Icahn School of Medicine at Mount Sinai spoke about what’s currently known about medical marijuana’s use, how CBD fits into the conversation, and what research still needs to be done.
CX-8998 Exhibits Promise in Essential Tremor Despite Failing to Meet Primary End Point
May 8th 2019Although the primary end point of centrally video-rated TETRAS Performance Subscale did not achieve statistical significance, CX-8998-treated patients showed significant improvements in a number of other measurements.
Amit Rakhit, MD, MBA: Developing Therapies for Fragile X Syndrome
May 8th 2019The chief medical officer and head of Research & Development at Ovid Therapeutics spoke about the Visual Analog Scale that the company developed to help better understand the impact that potential treatments have on patients with Fragile X syndrome.
Orally Dissolving Rimegepant Rapidly Lowers Pain, Improves Symptoms for Acute Migraine
May 7th 2019A 75 mg orally dissolving tablet formulation of the calcitonin gene-related peptide receptor antagonist met both co-primary end points of freedom from the patient-indicated most bothersome symptom and freedom from pain at 2 hours.
Fingolimod Reduces ARR in Patients With MS Who Switch From Other DMTs
May 7th 2019The sphingosine1-phosphate receptor modulator was shown to annualize relapse rates by more than 70% for patients switching from other disease-modifying therapies such as dimethyl fumarate; teriflunomide, and daclizumab.
CBD Has Potential for a Variety of Epilepsy Conditions, Expert Says
May 7th 2019The medical director of neurology and co-director of the Jane and John Justin Neurosciences Center at Cook Children’s Hospital spoke about what CBD has shown in clinical trials and how it could make an impact outside of Lennox-Gastaut and Dravet syndromes.
Eculizumab Significantly Reduces Relapse Risk in Neuromyelitis Optica Spectrum Disorder
May 7th 2019The treatment was efficacious in patients with AQP4-IgG-positive NMOSD, which accounts for nearly three-quarters of the population with the disorder, for which there is currently no approved treatment.
Jacqueline French, MD: Inhaled Alprazolam for Aborting Predictable Seizure Episodes in Epilepsy
May 6th 2019The professor of neurology and director of translational research and epilepsy clinical trials at NYU Langone spoke about the results of a phase 2b open-label feasibility study of this novel delivery method for abortive seizure treatment in patients with epilepsy.
Isradipine Fails to Slow Early Parkinson Disease Progression in Phase 3 Study
May 5th 2019Although animal models and early phase studies suggested some potential for the hypertension medication to slow disability progression in Parkinson disease, a phase 3 assessment showed a lack of treatment effect.